America of a famous hospital Scientists by Cancer A cell-killing drug has been developed that destroys solid tumors through ‘targeted chemotherapy’.
The pill contains a protein, for example, that acts like a ‘blizzard that can shut down an airline’s main hub and thus stop the flow of only planes carrying cancer cells.’
The protein was developed by a research team at City of Hope Hospital, one of the largest cancer research and treatment organizations in the United States.
A molecule called AOH1996 works by targeting the cancer variant of PCNA, a protein important for DNA replication and tumor growth.
Developed over the past two decades, this drug has proven effective in clinical research to treat breast, prostate, brain, ovarian, cervical, skin and lung cancers.
In this study, published in the medical journal ‘Cell Chemical Biology’, this protein was tested on more than 70 cancer cell lines.
This section contains related reference points (Related Nodes field).
The results showed that the AOH1996 molecule selectively killed cancer cells by disrupting the normal reproductive cycle of the cell. The next step is to advance these findings through clinical trials in humans.
Dr Linda Malkas, PhD, Professor of Molecular Diagnostics and Experimental Therapeutics at City of Hope and MT&BA Professor of Molecular Oncology, Ahmadineja said: ‘PCNA is like a large airline terminal hub with a More air gates are included. The data showed that PCNA is uniquely mutated in cancer cells and this fact helped us develop a drug that would target only the mutated form of PCNA in cancer cells. is.’
He added: ‘Our cancer-killing drug is like a blizzard that shuts down a major airline hub only to stop all flights carrying cancer cells.’
According to him: ‘The results have been promising. AOH1996 can inhibit tumor growth as a monotherapy without inducing toxicity in cell and animal models. The investigational chemotherapy is currently in a phase one human clinical trial at City of Hope.’
The study’s lead author, Long Guo, associate research professor in the Department of Molecular Diagnostics at Beckman Research Institute in the City of Hope, added: ‘No drug has ever targeted PCNA therapeutically. was made because it was considered ‘untreatable’ but clearly City of Hope was able to develop an investigational drug to target a challenging protein.’
According to him: ‘We discovered that PCNA is one of the possible causes of increased nucleic acid replication errors in cancer cells. Now that we know the specific part of the problem and can prevent it, we will go deeper to understand the process to develop more personalized and targeted cancer drugs.’
#Breakthrough #cancer #treatment #tumorkilling #drug #discovered
What types of cancers have demonstrated positive responses to the targeted chemotherapy drug AOH1996?
**Interview with Dr. Linda Malkas: A Breakthrough in Cancer Treatment**
**Editor:** Today, we have the privilege of speaking with Dr. Linda Malkas, a leading researcher at City of Hope Hospital, renowned for its groundbreaking work in cancer research. Dr. Malkas, congratulations on your team’s recent development of a targeted chemotherapy drug, AOH1996. Can you tell us more about how this drug works?
**Dr. Malkas:** Thank you for having me. AOH1996 is quite innovative as it utilizes a mechanism we compare to a ‘blizzard’ that disrupts the flow of cancer cells. Essentially, this drug targets a variant of the PCNA protein, which is crucial for DNA replication and tumor growth. By selectively shutting down this protein in cancer cells, we can effectively induce cell death without harming normal cells.
**Editor:** That sounds promising. What types of cancers have shown positive responses in clinical research?
**Dr. Malkas:** Our research has demonstrated effectiveness against several major cancer types, including breast, prostate, brain, ovarian, cervical, skin, and lung cancers. We conducted tests on over 70 different cancer cell lines, and the results were encouraging. AOH1996 selectively killed the cancer cells by disrupting their reproductive cycles.
**Editor:** What is the next step for your team following these promising results?
**Dr. Malkas:** The next critical phase involves advancing our findings into clinical trials with human participants. It’s an essential step to determine how safely and effectively AOH1996 works in actual patients.
**Editor:** It’s remarkable how far you’ve come in two decades of research. How do you feel about the potential impact of AOH1996 on cancer treatment?
**Dr. Malkas:** I believe AOH1996 could significantly change the landscape of cancer treatment. Targeted therapies offer the advantage of minimizing damage to healthy tissues, leading to fewer side effects compared to traditional chemotherapy. We are hopeful that this could improve patient outcomes and quality of life.
**Editor:** Thank you, Dr. Malkas, for sharing these insights. We look forward to hearing more about your progress in the clinical trials.
**Dr. Malkas:** Thank you for the opportunity. We’re excited about the potential to make a real difference in the lives of cancer patients.
